Who’s Hired? Makov To Step Away From Sun Pharma After 10 Years
Updates Also Announced By Mayne, Avet, Amneal And AAM
While Israel Makov steps away from Sun Pharmaceuticals, Mayne and Avet bring in new executives, Amneal appoints a new director and the AAM promotes a loyal colleague.
You may also be interested in...
Tildrakizumab, including Ilumetri end market numbers, nears $500m sales mark, with the contribution of Sun's wider specialty business nearly doubling since fiscal 2018. The anti-IL-23p19 monoclonal antibody has seen global sales spurt 81% in fiscal 2022, while acne therapy Winlevi has been well received by dermatologists in the US.
ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.
Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.